M&A Deal Summary

Covidien Acquires Nfocus Neuromedical

On February 19, 2013, Covidien acquired medical products company Nfocus Neuromedical for 72M USD

Acquisition Highlights
  • This is Covidien’s 13th transaction in the Medical Products sector.
  • This is Covidien’s 14th largest (disclosed) transaction.
  • This is Covidien’s 14th transaction in the United States.
  • This is Covidien’s 7th transaction in California.

M&A Deal Summary
Date 2013-02-19
Target Nfocus Neuromedical
Sector Medical Products
Buyer(s) Covidien
Deal Type Add-on Acquisition
Deal Value 72M USD

Target

Nfocus Neuromedical

Palo Alto, California, United States
Nfocus Neuromedical, Inc. is a neurovascular development, manufacturing and marketing company focused on treating hemorrhagic stroke.

Search 193,092 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Covidien

Dublin, Ireland

website

Category Company
Sector Medical Products
Employees38,500
Revenue 10.2B USD (2013)
DESCRIPTION
Covidien office in Plymouth, Minnesota.
Covidien office in Plymouth, Minnesota.

Covidien plc is a global healthcare technology and medical supplies provider. Covidien was formed as a spin-off from Tyco in 2007 and is based in Dublin, Ireland.

DEAL STATS #
Overall 18 of 21
Sector (Medical Products) 13 of 15
Type (Add-on Acquisition) 14 of 17
State (California) 7 of 8
Country (United States) 14 of 16
Year (2013) 1 of 2
Size (of disclosed) 14 of 14
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-12-26 CV Ingenuity

Fremont, California, United States

CV Ingenuity is a privately-held company focused on improving patient outcomes in the treatment of peripheral arterial disease (PAD) by providing solutions to relieve vascular obstructions, inhibit restenosis, and allow natural vessel healing. The company's core technology, while still in the investigational phase, is a Drug Coated Balloon (DCB) platform with a novel, proprietary, tunable, rapid-release system.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-06-28 Mallinckrodt

Dublin, United Kingdom

Mallinckrodt is a specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. Mallinckrodt was founded in 1867 and is based in Dublin, Ireland.

Sell -
Mergr

Product

Company

Legal